The FDA clearance for Lucid-MS Phase 2 is the primary catalyst — monitor for trial initiation, enrollment updates, and potential partnership interest. The extended cash runway reduces near-term dilution risk, but the stock remains binary on clinical data.
Price Chart
Executive Summary
Quantum BioPharma reported Q2 2026 EPS of -$0.71, a 21% miss vs consensus of -$0.59, but the headline event is the FDA clearance to proceed with the Lucid-MS Phase 2 trial in progressive multiple sclerosis. The company also reduced operating expenses 53% YoY and extended cash runway to at least October 2027, offsetting the earnings miss with a transformative regulatory milestone.
Key Financial Metrics
Key Facts
- FDA cleared IND for Lucid-MS Phase 2 trial in progressive MS (post-quarter, Aug 10, 2026)
- Q2 2026 EPS -$0.71 vs consensus -$0.59 (21.2% miss)
- Operating expenses down 53% YoY to $2.29M
- Cash, cash equivalents, and digital assets $9.5M (up from $4.1M at Dec 2025)
- Cash runway extended to at least October 2027 at current burn rate
- Shareholders' equity increased 19% to $6.09M
Financial Impact
FDA approval for Lucid-MS Phase 2 trial in progressive MS, a market expected to reach $38.62B by 2030; cash runway extended to October 2027; EPS miss of $0.12 per share vs consensus
Risk Factors
- Phase 2 trial may fail to meet endpoints, causing significant downside
- Pre-revenue biotech with no approved products; future financing likely needed
- Digital asset holdings introduce volatility to balance sheet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345231 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers